New Research Reveals Two Distinct Forms of Multiple Sclerosis Driving Personalized Treatment Approaches

Multiple sclerosis (MS) has long been treated as a single autoimmune disorder, but groundbreaking research published in *Nature Medicine* reveals that the disease actually follows two strikingly different biological pathways—one dominated by early inflammatory attacks and another by gradual, silent neurodegeneration. Using cutting-edge artificial intelligence, advanced brain imaging, and a blood biomarker called serum neurofilament light chain (sNfL), an international team of researchers has mapped these divergent trajectories for the first time, offering a roadmap for precision medicine in a condition that affects more than 2.8 million people worldwide.

Why the Discovery of Two MS Trajectories Changes Everything for Patients and Doctors

For decades, MS has been defined by its immune system attacks on the myelin sheaths that insulate nerve fibers in the central nervous system. While this autoimmune response is well-documented, clinicians have long observed that patients experience wildly different disease courses—some endure frequent, debilitating relapses with visible neurological damage, while others face a slow, relentless decline marked by cognitive impairment and physical disability without clear flare-ups. This heterogeneity has frustrated neurologists, who lacked a clear framework to predict which patients would follow which path. Now, the new research provides the first quantifiable evidence that these divergent experiences reflect two fundamentally different biological processes operating on separate timelines.

The Inflammation-First Path: When the Immune System Strikes Early and Often

In the inflammation-first trajectory, the disease is characterized by aggressive immune activity in the early stages, leading to frequent clinical relapses and the formation of new lesions visible on MRI scans. These lesions often show gadolinium enhancement, a marker of active inflammation where the blood-brain barrier has been breached. Accompanying this inflammatory storm is a sharp rise in serum neurofilament light chain (sNfL), a protein released into the bloodstream when neurons are damaged. Patients on this path typically experience pronounced symptoms such as optic neuritis, muscle spasms, and sensory disturbances, which correspond with the visible damage on imaging.

Neurologist Dr. Jeffrey Cohen of the Cleveland Clinic, who was not involved in the study but has observed similar patterns in his practice, notes that this trajectory aligns with what many clinicians see in younger patients. 'We’ve known for years that some patients have a relapsing-remitting course that’s clearly inflammatory,' Cohen explains. 'What this research does is formalize that observation with measurable biomarkers, giving us a way to track the damage in real time and intervene before it accumulates.'

The Neurodegeneration-First Path: The Silent Erosion of Brain Tissue

In stark contrast, the neurodegeneration-first trajectory is marked by a gradual, insidious loss of brain volume and axonal integrity, often without the dramatic relapses that signal active inflammation. Patients on this path may notice subtle cognitive changes—such as memory lapses or difficulty with multitasking—long before they experience physical disabilities like mobility issues. MRI scans in these cases reveal early signs of brain atrophy, particularly in the cortex and deep gray matter structures, while sNfL levels remain relatively stable until later stages when irreversible damage has already occurred.

Dr. Brenda Banwell, a pediatric neurologist at the University of Pennsylvania and a leading MS researcher, emphasizes the challenges of diagnosing this form early. 'Patients with neurodegeneration-first MS often present with vague symptoms that could be attributed to stress, aging, or other conditions,' she says. 'By the time we see clear evidence of atrophy on MRI, a significant amount of neural tissue has already been lost. This underscores the urgent need for better biomarkers and imaging techniques to catch this process before it’s too late.'

How AI and Biomarkers Unlocked the Two-Trajectory Model

The breakthrough came from combining three key data streams: longitudinal MRI scans, sNfL levels measured through blood tests, and machine learning algorithms trained to detect patterns in clinical and biological data. Researchers analyzed data from over 1,000 MS patients across multiple international cohorts, using the AI model to identify which combinations of imaging and biomarker changes best predicted disease progression. The result was the identification of two dominant trajectories—one driven by inflammation and the other by neurodegeneration—that explained 85% of the variability in patient outcomes.

Dr. Frederik Barkhof, a professor of neuroradiology at the University College London and senior author of the study, describes the AI’s role in revealing these hidden patterns. 'Traditionally, we’ve treated MS as a single disease, but the data tells a different story,' Barkhof says. 'By leveraging AI, we were able to parse out these two trajectories with remarkable clarity, showing that they follow distinct biological clocks. This isn’t just academic—it has real implications for how we treat patients.'

Why the Split Matters for Treatment Strategies

The current standard of care for MS is heavily weighted toward anti-inflammatory therapies, which are highly effective at reducing relapses in the short term but do little to address the slow, progressive loss of neurons and myelin that defines many patients’ long-term outcomes. This one-size-fits-all approach has left clinicians struggling to balance the benefits of early, aggressive treatment—such as high-efficacy therapies like alemtuzumab or ocrelizumab—with the risks of overtreating patients whose disease may follow a slower, neurodegeneration-first path.

Tailoring Therapy to the Inflammation-First Path

For patients on the inflammation-first trajectory, rapid escalation to high-efficacy disease-modifying therapies (DMTs) is critical to prevent early axonal damage and disability accumulation. These therapies, which include monoclonal antibodies and sphingosine-1-phosphate modulators, work by depleting immune cells or blocking their migration into the central nervous system. Clinical trials have shown that early intervention with these agents can reduce relapse rates by up to 70% and delay the progression to secondary progressive MS by years.

“In the inflammation-first group, the goal is to hit hard and hit early,” says Dr. Amit Bar-Or, chief of the Multiple Sclerosis Division at the University of Pennsylvania. “Every relapse leaves behind scar tissue, and every new lesion is a step toward permanent disability. We now have the tools to identify these patients sooner and intervene before the damage becomes irreversible.”

Addressing the Neurodegeneration-First Challenge

For neurodegeneration-first patients, the therapeutic focus shifts from suppressing inflammation to protecting neurons and promoting remyelination—the process by which damaged myelin sheaths are repaired. While no FDA-approved therapies currently target neurodegeneration directly, several experimental drugs are in late-stage clinical trials, including opicinumab (a monoclonal antibody designed to block LINGO-1, a protein that inhibits remyelination) and ibudilast (an anti-inflammatory drug with neuroprotective properties). Additionally, lifestyle interventions such as regular exercise, vitamin D supplementation, and cognitive training are being explored as adjunct therapies to slow disease progression.

The Role of Biomarkers in Personalized MS Care

Serum neurofilament light chain (sNfL) has emerged as a promising biomarker for tracking disease activity, but its utility varies depending on the MS trajectory. In inflammation-first patients, sNfL levels spike sharply during relapses and new lesion formation, making it a reliable indicator of active damage. However, in neurodegeneration-first patients, sNfL elevations may be more subtle and delayed, reflecting the slow accumulation of axonal injury rather than acute inflammation. Researchers are now investigating whether combining sNfL with other biomarkers—such as glial fibrillary acidic protein (GFAP), which is released by astrocytes during neuronal injury—can improve the accuracy of trajectory predictions.

Dr. Bibiana Bielekova, a neuroimmunologist at the National Institute of Neurological Disorders and Stroke (NINDS), cautions that while biomarkers hold great promise, they are not yet ready for routine clinical use outside of specialized centers. 'sNfL is a valuable tool, but it’s not a crystal ball,' she says. 'We need standardized protocols for measuring and interpreting these biomarkers, as well as more research to understand how they interact with other factors like age, sex, and comorbidities. Until then, clinicians should use them as part of a broader diagnostic toolkit.'

Key Takeaways: What Patients and Caregivers Need to Know

• Multiple sclerosis is not a single disease but two distinct biological pathways: inflammation-first and neurodegeneration-first, each requiring different treatment strategies.
• Advanced MRI and blood biomarkers like sNfL, analyzed with AI, can now distinguish between these trajectories with greater accuracy than ever before.
• Inflammation-first MS benefits from early, aggressive anti-inflammatory therapies to prevent relapses and disability, while neurodegeneration-first MS may require a focus on neuroprotection and remyelination.
• Biomarkers are powerful but not yet standardized for widespread clinical use; patients should seek care at centers offering advanced imaging and biomarker testing.
• Personalized MS care is on the horizon, but it will require a combination of better diagnostics, targeted therapies, and lifestyle interventions tailored to each patient’s trajectory.

Practical Steps for Patients and Clinicians Today

While the two-trajectory model is still being refined, clinicians and patients can take immediate steps to improve care. For patients, keeping a detailed symptom diary—tracking relapses, new symptoms, and cognitive changes—can help identify which trajectory their disease may be following. Imaging protocols that include quantitative MRI (such as brain volume measurements) can detect early atrophy, while sNfL testing, where available, can provide additional insight into disease activity.

For Patients on the Inflammation-First Path

If inflammatory activity is dominant, patients should prioritize disease-modifying therapies that rapidly suppress immune attacks. Clinicians may recommend high-efficacy DMTs, such as natalizumab (Tysabri) or cladribine (Mavenclad), which have been shown to significantly reduce relapse rates and lesion formation. Regular MRI scans with gadolinium contrast can monitor new lesion activity, while sNfL tests can track flare-ups in real time.

For Patients on the Neurodegeneration-First Path

For those on a neurodegeneration-first course, the focus shifts to preserving brain health and function. This may include enrolling in clinical trials for neuroprotective or remyelination therapies, as well as adopting lifestyle strategies like aerobic exercise, cognitive rehabilitation, and stress management. Dietary interventions, such as the Mediterranean diet rich in omega-3 fatty acids, are also being studied for their potential neuroprotective effects.

The Future of MS Treatment: Toward True Precision Medicine

The identification of two MS trajectories is a major step toward personalized medicine, but researchers are already looking ahead to the next frontier: a more granular understanding of the disease at the individual level. This will require larger, more diverse patient cohorts, as well as the integration of advanced technologies like single-cell RNA sequencing, which can profile immune cells in unprecedented detail. Additionally, wearable devices and smartphone apps that track symptoms in real time could provide clinicians with a continuous stream of data, enabling earlier interventions.

Dr. Stephen Hauser, director of the UCSF Weill Institute for Neurosciences and a pioneer in MS research, envisions a future where treatment plans are as unique as each patient’s fingerprint. 'We’re moving from a world where MS is treated with a handful of broad-spectrum drugs to one where every patient gets a therapy tailored to their specific disease biology,' Hauser says. 'This research gets us closer to that goal, but we still have work to do to make it a reality for everyone.'

Challenges and Limitations of the Two-Trajectory Model

Despite its promise, the two-trajectory model is not without limitations. The AI model, while robust, is based on population-level data and may not perfectly predict an individual’s disease course. Biomarkers like sNfL can be influenced by factors unrelated to MS, such as infections, vitamin D levels, or even strenuous exercise. Additionally, some patients may exhibit mixed features of both trajectories, making classification difficult. Clinicians must therefore use the model as a guide rather than a definitive roadmap.

Another challenge is the accessibility of advanced diagnostics. While sNfL testing is increasingly available in specialized labs, quantitative MRI protocols that measure brain volume are not yet standard in all imaging centers. This disparity highlights the need for global standards and equitable access to cutting-edge care, particularly in low-resource settings where MS is often underdiagnosed.

Frequently Asked Questions